Stillwater Capital Advisors LLC Purchases 2,170 Shares of Merck & Co., Inc. (NYSE:MRK)

Stillwater Capital Advisors LLC boosted its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,366 shares of the company’s stock after buying an additional 2,170 shares during the quarter. Merck & Co., Inc. makes up about 3.5% of Stillwater Capital Advisors LLC’s investment portfolio, making the stock its 7th largest position. Stillwater Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $19,088,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also bought and sold shares of the company. Bromfield Sneider Wealth Advisors acquired a new stake in Merck & Co., Inc. in the 1st quarter valued at $79,000. Hikari Power Ltd boosted its stake in Merck & Co., Inc. by 5.0% in the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock valued at $1,939,000 after buying an additional 1,130 shares in the last quarter. Financial Management Professionals Inc. boosted its stake in Merck & Co., Inc. by 9.3% in the 2nd quarter. Financial Management Professionals Inc. now owns 3,414 shares of the company’s stock valued at $311,000 after buying an additional 291 shares in the last quarter. ACG Wealth boosted its stake in Merck & Co., Inc. by 5.6% in the 1st quarter. ACG Wealth now owns 13,523 shares of the company’s stock valued at $1,110,000 after buying an additional 722 shares in the last quarter. Finally, Mascoma Wealth Management LLC boosted its stake in Merck & Co., Inc. by 36.4% in the 1st quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock valued at $76,000 after buying an additional 247 shares in the last quarter. Institutional investors and hedge funds own 73.33% of the company’s stock.

Merck & Co., Inc. Trading Up 3.5 %

NYSE MRK opened at $87.51 on Friday. The stock has a 50-day simple moving average of $88.83 and a 200 day simple moving average of $87.81. The company has a market capitalization of $221.69 billion, a PE ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66. Merck & Co., Inc. has a 12 month low of $71.50 and a 12 month high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.20. The business had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The firm’s revenue was up 28.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.31 earnings per share. Research analysts forecast that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be paid a $0.69 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.15%. Merck & Co., Inc.’s payout ratio is 42.27%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Atlantic Securities boosted their price objective on Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. SVB Leerink boosted their price objective on Merck & Co., Inc. from $105.00 to $109.00 and gave the stock an “outperform” rating in a research note on Monday, September 12th. Berenberg Bank raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $95.00 to $100.00 in a research note on Wednesday, September 14th. Cowen boosted their price objective on Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research note on Monday, June 27th. Finally, UBS Group boosted their price objective on Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a “neutral” rating in a research note on Monday, July 18th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $98.28.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.